Obesity Injections, Tirzepatide (Mounjaro)
A pathway is being developed in our ICB area (Northeast and North Cumbria) for the delivery of weight loss injections. We currently do not have a contract for delivering this at Scots Gap Medical Group. As soon as we are in a position to offer the treatment, we will update this notice.
To be eligible for the NHS injection a patient must have a BMI ≥40 and 4 out of the following 5 conditions.:
- Atherosclerotic Cardiovascular Disease – IHD, CVA/TIA, PAD, HF
- Hypertension – On treatment
- High Cholesterol – On Lipid Lowering Therapy (or LDL >=4.1 or HDL <1.0 for men or HDL <1.3 women or fasting triglycerides >=1.7)
- Obstructive Sleep Apnoea (OSA) – Meets criteria for CPAP or equivalent
- Diabetes Type 2
Phased Primary Care Cohorts (2025–2028)
The programme will develop over the coming years as follows:
- Cohort I (2025-26): 4 or more of the comorbidities listed above and BMI ≥40
- Cohort II (2026-27): 4 or more comorbidities listed above and BMI 35-39.9
- Cohort III (2026-2028): 3 or more comorbidities listed above and BMI ≥40
BMI thresholds should be reduced by 2.5 kg/m² for specified ethnicities, including South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean ethnicity